Fennec Pharmaceuticals Reports 78% Revenue Jump as Pedmark Demand Reaches Record High
Fennec's Pedmark is reportedly in demand as the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
Fennec's Pedmark is reportedly in demand as the only FDA-approved therapy to reduce cisplatin-induced hearing loss in pediatric patients.
In this op-ed, the authors share their perspective that because VA audiologists manage high patient volumes, diverse clinical needs and limited appointment time, hearing aid platforms must support efficient care without compromising individualized outcomes.
Hundreds of audiology students gathered at Starkey's headquarters for the 2026 Starkey University Workshop, engaging in hands-on learning and more.
WSA and the Academy of Doctors of Audiology have joined forces to bring a national public awareness and PSA campaign to adults 50 and older, positioning local audiologists as the front door to hearing care.
From building rapport to leveraging technology, HCPs share creative strategies to keep kids engaged for successful pediatric testing.
HearUSA has announced nationwide availability of the Signia Active Mini IX, a ready-to-wear in-the-ear device.